Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...
CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...
Leukemia and lymphoma are cancers that affect the blood or bone marrow. Fifteen percent of people with leukemia have chronic myeloid leukemia (CML), which has seen a 55% jump in new cases over the ...
Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database Overall, 395 Ethiopian patients were enrolled between ...
Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...
Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.
CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...
Danziten, a nilotinib formulation, is approved for CML without mealtime restrictions, enhancing patient adherence and reducing cardiotoxicity risks. The drug offers equivalent efficacy to Tasigna, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results